Thymalfasin
- Product NameThymalfasin
- CAS69440-99-9
- MFC129H215N33O55
- MW0
- EINECS1592732-453-0
- MOL FileMol File
Usage And Synthesis
1. Biochemical Extraction Method
Thymosin peptide preparations (mixtures of various peptides) are primarily obtained from animal tissues, resulting in significant differences in activity. Because they contain animal proteins, the likelihood of allergic reactions is relatively high. Thymalfasin, extracted biochemically from human embryonic thymus, has a low yield but good efficacy. Considering the limited availability of raw materials, high price, low yield, and complex extraction steps, large-scale production faces numerous difficulties, and its development prospects are not optimistic.
2. Chemical Synthesis Method
Commercially available Thymalfasin is mainly synthesized using the SPSS method, with synthesis and purification achieved through appropriate techniques. Using resin as a carrier, solid-phase synthesis is performed using Fmoc. 28 amino acids are sequentially coupled according to the Thymalfasin formula. The N-terminal amino acid is acetylated with acetic anhydride, and cleavage is performed using TFA as the main cleavage reagent to obtain the crude product. The crude product is then purified by HPLC to obtain pure Thymalfasin, which is further purified to obtain the Thymalfasin raw material.
3. Genetic Engineering Methods
There are three ways to obtain genetically engineered bacteria:
(1) Cloning a multi-heterogeneous gene into a host to obtain the target gene bacteria, which are then expressed as inclusion bodies. It has been reported that a multi-heterogeneous gene of thymosin was constructed using random annealing and PCR techniques and cloned into *E. coli*.
(2) Recombining the synthesized fusion protein gene into a vector and transforming the vector into a host to construct genetically engineered bacteria. For example, based on the signal peptide gene in the plasmid, an expression plasmid was constructed, transformed into *Pichia pastoris* by electroporation, and then the fusion protein was expressed by methanol induction, followed by enzyme digestion to obtain thymosin.
(3) First, an expression vector was constructed and transformed into a host to become a genetically engineered bacterium, then fermented to obtain the target product. The synthesized thymosin alpha monomer gene is ligated to the corresponding plasmid to construct an expression vector, which is then integrated into Pichia pastoris. The target product is directly secreted into the fermentation broth, and high-purity thymosin alpha is obtained through two-step purification. This method involves fewer separation steps, lower cost, and is easy to scale up for production.
Thymosin peptide preparations (mixtures of various peptides) are primarily obtained from animal tissues, resulting in significant differences in activity. Because they contain animal proteins, the likelihood of allergic reactions is relatively high. Thymalfasin, extracted biochemically from human embryonic thymus, has a low yield but good efficacy. Considering the limited availability of raw materials, high price, low yield, and complex extraction steps, large-scale production faces numerous difficulties, and its development prospects are not optimistic.
2. Chemical Synthesis Method
Commercially available Thymalfasin is mainly synthesized using the SPSS method, with synthesis and purification achieved through appropriate techniques. Using resin as a carrier, solid-phase synthesis is performed using Fmoc. 28 amino acids are sequentially coupled according to the Thymalfasin formula. The N-terminal amino acid is acetylated with acetic anhydride, and cleavage is performed using TFA as the main cleavage reagent to obtain the crude product. The crude product is then purified by HPLC to obtain pure Thymalfasin, which is further purified to obtain the Thymalfasin raw material.
3. Genetic Engineering Methods
There are three ways to obtain genetically engineered bacteria:
(1) Cloning a multi-heterogeneous gene into a host to obtain the target gene bacteria, which are then expressed as inclusion bodies. It has been reported that a multi-heterogeneous gene of thymosin was constructed using random annealing and PCR techniques and cloned into *E. coli*.
(2) Recombining the synthesized fusion protein gene into a vector and transforming the vector into a host to construct genetically engineered bacteria. For example, based on the signal peptide gene in the plasmid, an expression plasmid was constructed, transformed into *Pichia pastoris* by electroporation, and then the fusion protein was expressed by methanol induction, followed by enzyme digestion to obtain thymosin.
(3) First, an expression vector was constructed and transformed into a host to become a genetically engineered bacterium, then fermented to obtain the target product. The synthesized thymosin alpha monomer gene is ligated to the corresponding plasmid to construct an expression vector, which is then integrated into Pichia pastoris. The target product is directly secreted into the fermentation broth, and high-purity thymosin alpha is obtained through two-step purification. This method involves fewer separation steps, lower cost, and is easy to scale up for production.
Thymalfasin is an important peptide drug widely used for the single or combination treatment of hepatitis, sepsis, cancer, and immunodeficiency.
Thymalfasin is a 28-amino acid peptide with immunomodulatory activity that has demonstrated therapeutic potential in a variety of diseases, including viral hepatitis. It enhances T-cell function, exhibits antiviral activity and increases intracellular glutathione levels. This is primarily manifested in its ability to promote T-cell differentiation and/or maturation, increase the production of interferon-gamma (IFN-γ), IL-2 and IL-3, enhance natural killer (NK) cell activity, and promote the production of migration inhibitory factor (MIF). In vitro studies indicate that it counteracts T-cell apoptosis in thymocytes. Its antiviral action involves inhibiting viral replication by increasing the expression of MHC class I molecules and reducing viral replication in infected cells cultured in vitro. Thymalfasin also elevates intracellular glutathione levels, and this increase in glutathione is crucial for significantly reducing viral replication[1].
Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases, including chronic hepatitis B and C, AIDS, primary immunodeficiency diseases, depressed response to vaccination and cancer.
The primary mechanism by which Thymalfasin operates involves bolstering the immune system. Thymosin Alpha-1, the active component of Thymalfasin, is known to enhance T-cell function. T-cells are a type of white blood cell crucial for adaptive immunity. By promoting the maturation and differentiation of these cells, Thymalfasin aids the body in mounting a more effective immune response against pathogens and malignant cells. Additionally, Thymalfasin has been observed to increase the production of various cytokines, including interleukin-2 (IL-2) and interferon-gamma (IFN-γ). These cytokines play a pivotal role in regulating immune responses and activating other immune cells. Furthermore, Thymalfasin has demonstrated the ability to enhance the activity of natural killer (NK) cells, which are essential for the innate immune response against virally infected cells and tumors. The peptide also exhibits anti-inflammatory properties, making it a multifaceted tool in the arsenal of immunotherapy.
[1] A. Ciancio, & M. R. (2010). Thymalfasin in the treatment of hepatitis B and C. Annals of the New York Academy of Sciences, 1194 1, 141–146. https://doi.org/10.1111/j.1749-6632.2010.05487.x
Related articles
PROMPT×
PROMPT
The What'sApp is temporarily not supported in mainland China
The What'sApp is temporarily not supported in mainland China
Cancel
Determine